UroGen Pharma Ltd. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2014 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
UroGen Pharma Ltd. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2014 to Q4 2023.
  • UroGen Pharma Ltd. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $144M, a 10.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $144M +$14M +10.8% Dec 31, 2023 10-K 2024-03-14
Q4 2022 $130M +$29M +28.8% Dec 31, 2022 10-K 2024-03-14
Q4 2021 $101M +$23.7M +30.7% Dec 31, 2021 10-K 2024-03-14
Q4 2020 $77M +$26.4M +52.1% Dec 31, 2020 10-K 2023-03-24
Q4 2019 $50.6M +$22.3M +79.1% Dec 31, 2019 10-K 2022-03-21
Q4 2018 $28.2M +$16.5M +141% Dec 31, 2018 10-K 2021-03-18
Q4 2017 $11.7M +$7.57M +182% Dec 31, 2017 10-K 2020-03-02
Q4 2016 $4.16M -$341K -7.58% Dec 31, 2016 10-K 2020-03-02
Q4 2015 $4.5M +$1.95M +76.4% Dec 31, 2015 10-K 2019-02-28
Q4 2014 $2.55M Dec 31, 2014 20-F 2018-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.